This grant is a response to RFA CA-15-008, question 1: For tumors that arise from a pre-malignant field, what properties of cells in this field can be used to design strategies to inhibit the development of future tumors? A key question we address is how the pre-malignant field specifically reshapes the epigenetic landscape of emerging cancers to promote metastatic behavior, which accounts for the majority of cancer-related deaths. Even prior to malignant transformation, the epigenome destabilizes and degrades lineage specific expression patterns. Since chromatin modifications respond to environmental cues, these early epigenetic shifts are likely to be critical in understanding how the tumorigenic microenvironment determines subsequent cancer cell phenotype. However, very few studies have addressed the process by which the pre-malignant environment broadly reshapes the epigenome. Enhancers are key elements that control cell-type specific gene expression patterns, and are activated in a coordinated fashion to determine cell lineage. We have identified novel enhancers of the SHC1 gene which drive expression of the lineage-specific isoform p66Shc, a protein that controls anoikis and functions as a strong metastasis suppressor. In metastatic lung cancer cells, we find that Aiolos, a chromatin regulator normally involved in lymphocyte lineage determination, silences p66Shc enhancers. Aiolos also silences putative enhancers of multiple adhesion-related genes besides SHC1, while also inducing lymphocyte homing receptors. In human tumors, high levels of Aiolos correlate with markedly worse survival rates. Further, we note aberrant expression of Aiolos by IHC in normal-appearing bronchial epithelium adjacent to Aiolos-positive lung tumors but not in epithelium remote from these tumors, suggesting an epigenetic field defect inherited by lung cancer cells. Finally, we replicate the induction of Aiolos in lung cancer cells through exposure to specific inflammatory factors know to both promote inflammation-associated tumorigenesis and drive lymphocyte differentiation. In this proposal, we hypothesize that such factors within an inflammatory pre-malignant field shift the enhancer landscape of lung epithelium and confer certain lymphocyte-like properties that promote lethal complications such as metastasis. In the first Aim we will define enhancer constituents of the gene for Aiolos responsive to such factors. In the second aim we will construct an epigenome-wide map of enhancers either activated or decommissioned in association with Aiolos induction, to identify patterns responsible for changes in epithelial cell phenotype. In the third aim we will compare these enhancer landscapes to those found in lung tumor epithelium in comparison with those in histologically normal lung epithelium from tumor-adjacent and remote tissues. In the fourth aim we will attempt to rewrite Aiolos- directed histone modifications through functional epigenomics. This project charts new territory in both the conceptual basis of tumor metastasis and in the design of novel therapeutic approaches against it.

Public Health Relevance

Epigenetics is the study of cellular inheritance of gene expression programs that do not have a mutational basis. In this proposal, we will study the effect of the abnormal, inflamed lung in preparing the lung cell epigenetic profile to yield cancers that start to mimic certain inflammatory cell behaviors. Specifically, the resultant tumor cells are predicted to have ability to travel throughout the body much like an inflammatory cell. Since metastasis accounts for ~90% of cancer-related deaths (still the number one killer of Americans), this project has substantial public health implications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA208620-04
Application #
9743095
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Johnson, Ronald L
Project Start
2016-09-01
Project End
2021-08-31
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
4
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Li, Xichuan; Lin, Zhenzhen; Wang, Hao et al. (2018) Heritable, allele-specific chromosomal looping between tandem promoters specifies promoter usage of SHC1. Mol Cell Biol :
Mu, Yanchao; Yan, Xiaojie; Li, Ding et al. (2018) NUPR1 maintains autolysosomal efflux by activating SNAP25 transcription in cancer cells. Autophagy 14:654-670
Ochoa, Cristhiaan D; Wu, Ru Feng; Terada, Lance S (2018) ROS signaling and ER stress in cardiovascular disease. Mol Aspects Med 63:18-29
Sacharidou, Anastasia; Chambliss, Ken L; Ulrich, Victoria et al. (2018) Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium. Blood 131:2097-2110
Wu, Ru Feng; Liao, Chengxu; Hatoum, Hadi et al. (2017) RasGRF Couples Nox4-Dependent Endoplasmic Reticulum Signaling to Ras. Arterioscler Thromb Vasc Biol 37:98-107
Abid, Shadaan; Xie, ShangKui; Bose, Moumita et al. (2017) 17?-Estradiol Dysregulates Innate Immune Responses to Pseudomonas aeruginosa Respiratory Infection and Is Modulated by Estrogen Receptor Antagonism. Infect Immun 85:
Wu, Ru-Feng; Liao, Chengxu; Fu, Guosheng et al. (2016) p66Shc couples mechanical signals to RhoA through FAK-dependent recruitment of p115-RhoGEF and GEF-H1. Mol Cell Biol :
Du, Wei; Jiang, Yuan; Zheng, Zhichao et al. (2013) Feedback loop between p66(Shc) and Nrf2 promotes lung cancer progression. Cancer Lett 337:58-65